Zinc-hydroxychloroquine found effective in some COVID-19 patients, says study

Packets of a Nivaquine, tablets containing chloroquine and Plaqueril, tablets containing hydroxychloroquine, drugs that have shown signs of effectiveness against coronavirus. Image: AFP/Gerard Julien

The antimalarial drug hydroxychloroquine has shown mixed results against the coronavirus in early studies, but a new paper out of New York suggests combining it with the dietary supplement zinc sulfate could create a more effective treatment.

The research by the New York University Grossman School of Medicine was posted on a medical preprint site on Monday, meaning it has not yet been peer reviewed.

Records of about 900 COVID-19 patients were reviewed in the analysis, with roughly half given zinc sulfate along with hydroxychloroquine and the antibiotic azithromycin.

The other half only received hydroxychloroquine and azithromycin.

Those receiving the triple-drug combination had a 1.5 times greater likelihood of recovering enough to be discharged, and were 44% less likely to die, compared to the double-drug combination.

It did not, however, change the average time patients spent in a hospital (six days), the time they spent on the ventilator (five days) or the total amount of oxygen required.

Senior investigator and infectious disease specialist Joseph Rahimian told Agence France-Presse it was the first study to compare the two combinations.

But he cautioned that a controlled experiment would be needed to prove the benefits beyond doubt.

“The next logical step would be to do a prospective study to see if this holds up in people that you give zinc to, and then you watch and compare,” he said.

Hydroxychloroquine has been proposed as a treatment against the SARS-CoV-2 virus because it has antiviral properties that have been proven in lab settings, but not in people.

It interferes with the virus’ ability to enter the cells — and also seems to block them from replicating once they are already inside.

Zinc itself has antiviral properties and past research has suggested it may reduce the time people suffer from common colds.

Rahimian said that it may be that when used to treat coronavirus patients, it is the zinc that does the heavy lifting and is the primary substance attacking the pathogen.

Hydroxychloroquine, on the other hand, acts as an agent that transports the zinc into cells, increasing its efficacy, he suggested. RGA

RELATED STORIES: 

No apparent harm or benefit from hydroxychloroquine—study

Belgian llama holds key to possible coronavirus treatment